serlopitant
Sponsors
Vyne Therapeutics Inc.
Conditions
BurnsPrurigo NodularisPruritus
Phase 2
A Randomized Placebo-Controlled Study of the Neurokinin-1 (NK1) Receptor Antagonist Serlopitant Prurigo Nodularis (PN)
CompletedNCT02196324
Start: 2014-07-09End: 2016-06-10Updated: 2021-05-20
Study of the Efficacy, Safety & Tolerability of Serlopitant for Pruritus (Itch) After Burn Injury
TerminatedNCT02975271
Start: 2016-11-30End: 2017-01-17Updated: 2021-05-20